Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on February 1, 2023. The Company is incorporated in Delaware and its Class A common stock trades on the NASDAQ Capital Market under the symbol VTVT. The report primarily addresses a corporate governance event under Item 8.01 (Other Events).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event notification and does not contain financial statements or performance metrics.
Material Changes
The material change reported is an executive appointment:
- Effective Date: February 1, 2023 (immediately).
- Appointment: Elizabeth Keiley has been appointed as Executive Vice President and General Counsel.
- Authority: The appointment was made by the Board of Directors.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook statements, or specific risk disclosures beyond the standard incorporation of the attached press release (Exhibit 99.1). No unusual items or contingencies are detailed in the text of this report.
Investor Verification Checklist
- Verify the background and qualifications of the newly appointed Executive Vice President and General Counsel, Elizabeth Keiley.
- Review the attached Press Release (Exhibit 99.1) for additional context regarding the leadership change.
- Confirm the Company's current cash position and runway in the most recent 10-Q or 10-K, as this 8-K does not provide financial data.